US4446129A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treatment of arthrosis deformans with elastase
Assignee: Eisai Co Ltd
•
Filing: 1983-09-02
•
Granted: 1984-05-01
•
Expires: 2003-09-02
Abstract
Abstract A method is disclosed for treating a subject suffering from arthrosis deformans which comprises administering to said subject a therapeutically effective amount of a composition comprising elastase and a pharmacologically acceptable carrier. Particularly excellent results were obtained using this method for the treatment of gonarthrosis deformans.
Inventors
- 👤 Tohru Sawada
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 09:01
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/482; A61K38/486; A61P; A61P3/00; A61P43/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
30 words
A method for treating a subject suffering from arthrosis deformans which comprises administering to said subject a therapeutically effective amount of a composition comprising elastase and a pharmacologically acceptable carrier.
Claim 2
Independent Claim
30 words
A method for treating a subject suffering from arthrosis deformans which comprises administering to said subject a therapeutically effective amount of a composition comprising elastase and a pharmacologically acceptable carrier.
Claim 3
Dependent Claim
14 words
A method as claimed in claim 1, wherein said subject is a human being.
Claim 4
Dependent Claim
15 words
A method as claimed in claim 2, wherein said subject is suffering from gonarthrosis deformans.
Claim 5
Dependent Claim
15 words
A method as claimed in claim 2, wherein said subject is suffering from coxarthrosis deformans.
Claim 6
Dependent Claim
13 words
A method as claimed in claim 1, wherein said elastase is porcine elastase.
Claim 7
Dependent Claim
32 words
A method as claimed in claim 5, wherein said porcine elastase has a molecular weight of 25,900, an isoelectric point of pH 9.5±0.5, and a sedimentation coefficient S 20 ,w of 2.6.
Claim 8
Dependent Claim
13 words
A method as claimed in claim 2, wherein said composition is administered orally.
Claim 9
Dependent Claim
29 words
A method according to claim 7, wherein said composition is administered to said human subject at a dosage in the range of from 2,000 to 20,000 EL. U day.
Claim 10
Dependent Claim
27 words
A method according to claim 8, wherein said composition is administered to said human subject over a period in the range of from 4 to 20 weeks.
Claim 11
Dependent Claim
36 words
A method according to claim 9, wherein said composition consists essentially of elastase, lactose, starch, cellulose and a binder, and is formulated into a solid preparation selected from the group consisting of granules, tablets and capsules.
References Cited (Backward Citations)
US4397951A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-05-01 | 1987-10-31 | 1988-05-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-05-01 | 1991-10-31 | 1992-05-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-05-01 | 1995-10-31 | 1996-05-01 | $7700.00 | Window Closed / Lapsed |